Novavax Inc. (NVAX) is a publicly traded pharmaceutical company in the business of developing products to prevent and treat infectious diseases, including respiratory syncytial virus (RSV), seasonal influenza, and human metapneumovirus (hMPV). The company was founded in 1993 and has its headquarters in Maryland. It has a market cap of $1 billion and trades at $4 per share after earning an EPS of $-0.59 during Q3 2017 with revenues of $8 million. It currently employs 577 people and trades on the NASDAQ under the ticker symbol NVAX.
Company Summary
Novavax is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of vaccines to prevent serious infectious diseases. The company’s proprietary adjuvant technology, Matrix-MTM, is the only adjuvant approved for use in humans by the U.S. Food and Drug Administration (FDA). Novavax has licensed this technology to GlaxoSmithKline (GSK) for certain of its vaccines. In addition to developing its own products, Novavax has collaborations with Sanofi Pasteur, the Serum Institute of India Ltd., and the Walter Reed Army Institute of Research (WRAIR).
Novax is classified as a growth company, if you are looking to invest in a growth company you should be aware of the risks involved.
What They Do
Novavax is a clinical-stage vaccine company with a mission to protect people of all ages from serious and life-threatening diseases. Their primary focus is on the respiratory syncytial virus (RSV), pandemic influenza, and other infectious diseases.
The company has yet to bring any products to market, which makes it a high-risk investment. However, their technology has shown promise in early clinical trials. If they are able to successfully commercialize their vaccines, Novavax could see exponential growth.
Key Statistics
Novavax is a clinical-stage vaccine company with a market cap of $4.79 billion.
Novax revenue is currently $1.3B The company’s most advanced product is a Phase 3 clinical trial for NVX-CoV2373, its COVID-19 vaccine candidate. Novavax has yet to bring a product to market and is not profitable. The stock is down 36% year-to-date.
Valuation and Conclusion
Novavax is a clinical-stage vaccine company with a promising technology platform and a number of vaccine candidates in development. However, the company is still pre-revenue and faces significant risks. As such, Novavax is a high-risk, high-reward stock. While the potential upside is large, investors should be aware of the risks before investing.
